An interventional study of Experimental: AI-Based Personalized Self-Management Intervention and Behavioral: AI-Based Personalized Self-Management Intervention in Heart Failure, sponsored by Alexandria University. Not yet recruiting at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Alexandria University · Not applicable, Interventional, and Supportive care
Among 63 studies in Heart Failure with a site in Egypt — 16 open to participants now, 21 under way, 2 of them phase 3. Heart Failure · Egypt.
Among the 63 studies in Heart Failure with a site in Egypt, this one is the 7th largest by planned enrollment of the 46 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 with no phase, reaches primary completion later than 13 of the 20 other live ones, and was the 62nd registered.
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
Browse Heart Failure studies →16 of the 63 studies in Heart Failure with a site in Egypt are open now. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 45–65
Tanta University · Sites in Egypt
Ages 18+
Future University in Egypt · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 1 mo–18 yrs
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 6 · Phase 4 12
First in 2014; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 68 across the 46 interventional studies, 140 across the 17 observational. Of the 33 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 63 have an industry lead sponsor. The 10 most frequent:
Alexandria University is the lead sponsor of 606 studies on the registry; 141 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Alexandria University has 6 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07841665Alexandria UniversityAI-Based Personalized Self-Management for Patients With Heart Failure | 2026-12 |
| NCT07692256Ain Shams Universitythe Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients | 2026-12-01 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT07930390Alexandria UniversityHandheld Fan Direction for Breathlessness in Chronic Heart and Lung Disease | 2027-02-03 |
| NCT07394270German University in CairoEffect of Add-on L-Arginine Therapy on Heart Failure Patients | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Heart Failure with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effectiveness of an AI-based personalized self-management intervention on self-care behaviors and health-related quality of life among patients with chronic heart failure. Using a two-phase sequential explanatory mixed-methods design, Phase I consists of a randomized controlled trial comparing a 12-week AI-guided self-management intervention plus usual care with usual care alone. Self-care behaviors and health-related quality of life will be assessed at baseline, 6 weeks, and 12 weeks. Phase II will involve semi-structured interviews with a purposively selected subgroup of intervention participants to explore their experiences with the AI-based intervention and to explain the quantitative findings. The study seeks to generate evidence on the effectiveness and patient acceptability of AI-supported self-management in heart failure care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligibility Criteria
Inclusion Criteria:
Adults aged 18 years or older. Confirmed diagnosis of chronic heart failure ( Class II or III). Clinically stable for at least 1 month before enrollment. Able to read and understand Arabic. Own or have regular access to a smartphone compatible with the AI-based application.
Willing and able to provide and participate throughout the 12-week study period.
Exclusion Criteria:
Class IV or end-stage heart failure. Severe cognitive impairment or any condition preventing reliable self-reporting or .
Severe psychiatric illness that may interfere with study participation. Participation in another heart failure self-management or behavioral intervention program during the study period.
Inability to use a smartphone or the study application despite orientation and support.
Any serious medical condition deemed by the investigators to make participation inappropriate or unsafe.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Experimental: AI-Based Personalized Self-Management Intervention
Behavioral: Behavioral: AI-Based Personalized Self-Management Intervention
Participants receive a smartphone-based AI application delivering personalized self-management support for 12 weeks, including symptom monitoring, individualized self-care recommendations, medication and lifestyle reminders, educational content, and real-time guidance alongside usual care.
Participants receive routine heart failure care, including standard education, outpatient follow-up, and prescribed treatment, without access to the AI-based application.
Primary Outcome Measure 1: Self-Care Behavior (EHFScBS-9)
Description: Change in self-care behavior measured using the 9-item European Heart Failure Self-Care Behaviour Scale (EHFScBS-9). Scores are transformed to a 0-100 scale, with higher scores indicating better self-care behavior.
Time frame: Time Frame: Baseline, Week 6, and Week 12
Primary Outcome Measure 2: Health-Related Quality of Life (RAND-36)
Description: Change in health-related quality of life measured using the RAND 36-Item Health Survey (RAND-36). Scores are transformed to a 0-100 scale, with higher scores indicating better health-related quality of life.
Time frame: Time Frame: Baseline, Week 6, and Week 12
Secondary Outcome Measure 1: Technology Acceptance of the AI-Based Intervention
Description: Technology acceptance measured using an adapted AI Technology Acceptance Questionnaire based on the Modified Technology Acceptance Model (mTAM). The instrument consists of 16 items assessing Perceived Usefulness, Perceived Ease of Use, Behavioral Intention, and User Satisfaction. Items are rated on a 7-point Likert scale, with higher scores indicating greater acceptance of the AI-based intervention.
Time frame: Time Frame: Week 12
Secondary Outcome Measure 2: Participants' Experiences With the AI-Based Intervention
Description: Participants' experiences, perceived benefits, barriers, facilitators, and recommendations regarding the AI-based personalized self-management intervention, assessed through semi-structured interviews and analyzed using thematic analysis.
Time frame: Time Frame: after completion of the 12-week intervention.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 2 months is below that.
Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.